ArticleCase reports in dermatological medicine2026
Achieving Steroid-Sparing Remission in Refractory Pyoderma Gangrenosum With an Integrative Meta-Therapeutic System Based on Traditionally Engineered Nanomercury Sulfide: A Case Series.
Article in Case reports in dermatological medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Achieving Steroid-Sparing Remission in Refractory Pyoderma Gangrenosum With an Integrative Meta-Therapeutic System Based on Traditionally Engineered Nanomercury Sulfide: A Case Series.Case reports in dermatological medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of pyoderma gangrenosum (PG) remains a formidable clinical challenge due to its complex, multipathway immunopathogenesis. Although conventional steroid therapy and advanced biologic agents have improved outcomes, a substantial proportion of patients, particularly those with severe, progressive ulceration, exhibit treatment-refractory disease, highlighting a critical unmet need for novel strategies capable of network-level immune modulation. To address this, we designed and implemented a self-regulating, integrative meta-therapeutic system centered on a nanostructured, herbo-metallic core of traditionally processed mercury sulfide (HgS) called Linga Chenduram, a compound characterized by its stable crystalline lattice and a toxicokinetic profile favoring particulate clearance. This system synergistically combines the nanocore with adjunctive phytocompounds (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.